Adaptive Biotechnologies

Historical price data

Adaptive Biotechnologies is a commercial-stage company on a mission to harness the adaptive immune system as a natural diagnostic and therapeutic tool. Its core achievement is the development of the Immune Medicine Platform, which sequences and maps immune receptors at scale, enabling both its growing clonoSEQ MRD diagnostics business and a deep drug discovery pipeline. The company's strategy is to leverage its unique, data-generating platform to create a sustainable competitive moat across both diagnostics and therapeutics, aiming to transform the detection, monitoring, and treatment of disease.

Adaptive's Immune Medicine Platform is an integrated system that sequences, maps, pairs, and characterizes T-cell and B-cell receptors at scale, translating immune system genetics into diagnostic signatures and therapeutic candidates.

In MRD diagnostics, Adaptive competes with NGS players like Guardant Health and PCR-based methods. In therapeutics, it faces TCR specialists like Immunocore and antibody discovery platforms like AbCellera. Its integrated data-generating platform and first-mover FDA clearances are key differentiators.